Form 4 for CCCC C4 Therapeutics, Inc.
Accepted 2024-10-02 00:00:00 ET · period of report 2024-10-01 · accession 0001662579-24-000090 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-10-02 | 2024-10-01 | CCCC | GROGAN DONNA ROY | Dir | A - Grant | $5.56 | +2,474 | 28.9K | +9% | +$13.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-01 | A | A | 2,474 | $5.56 | 28,942 | D | — | — | (F1) These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. (F2) The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2024. |